218 related articles for article (PubMed ID: 29577257)
21. Predictive value of the HAS-BLED and ATRIA bleeding scores for the risk of serious bleeding in a "real-world" population with atrial fibrillation receiving anticoagulant therapy.
Roldán V; Marín F; Fernández H; Manzano-Fernandez S; Gallego P; Valdés M; Vicente V; Lip GYH
Chest; 2013 Jan; 143(1):179-184. PubMed ID: 22722228
[TBL] [Abstract][Full Text] [Related]
22. The HAS-BLED, ATRIA, and ORBIT Bleeding Scores in Atrial Fibrillation Patients Using Non-Vitamin K Antagonist Oral Anticoagulants.
Lip GYH; Skjøth F; Nielsen PB; Kjældgaard JN; Larsen TB
Am J Med; 2018 May; 131(5):574.e13-574.e27. PubMed ID: 29274754
[TBL] [Abstract][Full Text] [Related]
23. Mutations in CYP2C9 and/or VKORC1 haplotype are associated with higher bleeding complications in patients with Budd-Chiari syndrome on warfarin.
Shukla A; Jain A; Kahalekar V; Bendkhale S; Gogtay N; Thatte U; Bhatia S
Hepatol Int; 2019 Mar; 13(2):214-221. PubMed ID: 30617764
[TBL] [Abstract][Full Text] [Related]
24. Influence of genetic and non-genetic factors on acenocoumarol maintenance dose requirement in a Tunisian population.
Ajmi M; Omezzine A; Achour S; Amor D; Hamdouni H; Ismaïl FBF; Rejeb NB; Kechrid CL; Boughzela E; Bouslama A
Eur J Clin Pharmacol; 2018 Jun; 74(6):711-722. PubMed ID: 29479633
[TBL] [Abstract][Full Text] [Related]
25. Prediction of long-term net clinical outcomes using the TIMI-AF score: Comparison with CHA
Rivera-Caravaca JM; Roldán V; Esteve-Pastor MA; Valdés M; Vicente V; Marín F; Lip GYH
Am Heart J; 2018 Mar; 197():27-34. PubMed ID: 29447781
[TBL] [Abstract][Full Text] [Related]
26. Predictive abilities of the HAS-BLED and ORBIT bleeding risk scores in non-warfarin anticoagulated atrial fibrillation patients: An ancillary analysis from the AMADEUS trial.
Senoo K; Lip GY
Int J Cardiol; 2016 Oct; 221():379-82. PubMed ID: 27409565
[TBL] [Abstract][Full Text] [Related]
27. VKORC1 and CYP2C9 polymorphisms related to adverse events in case-control cohort of anticoagulated patients.
Misasi S; Martini G; Paoletti O; Calza S; Scovoli G; Marengoni A; Testa S; Caimi L; Marchina E
Medicine (Baltimore); 2016 Dec; 95(52):e5451. PubMed ID: 28033245
[TBL] [Abstract][Full Text] [Related]
28. Predicting Bleeding Events in Anticoagulated Patients With Atrial Fibrillation: A Comparison Between the HAS-BLED and GARFIELD-AF Bleeding Scores.
Proietti M; Rivera-Caravaca JM; Esteve-Pastor MA; Romiti GF; Marin F; Lip GYH
J Am Heart Assoc; 2018 Sep; 7(18):e009766. PubMed ID: 30371183
[TBL] [Abstract][Full Text] [Related]
29. Assessing the risk of bleeding in patients with atrial fibrillation: the Loire Valley Atrial Fibrillation project.
Lip GY; Banerjee A; Lagrenade I; Lane DA; Taillandier S; Fauchier L
Circ Arrhythm Electrophysiol; 2012 Oct; 5(5):941-8. PubMed ID: 22923275
[TBL] [Abstract][Full Text] [Related]
30. The bleeding risk during warfarin therapy is associated with the number of variant alleles of CYP2C9 and VKORC1 genes.
Tomek A; Maťoška V; Kolářová T; Neumann J; Srámek M; Sarbochová I; Táborský L; Bojar M; Goetz P; Serebruany VL
Cardiology; 2013; 125(3):182-91. PubMed ID: 23774101
[TBL] [Abstract][Full Text] [Related]
31. Major bleeding and intracranial hemorrhage risk prediction in patients with atrial fibrillation: Attention to modifiable bleeding risk factors or use of a bleeding risk stratification score? A nationwide cohort study.
Chao TF; Lip GYH; Lin YJ; Chang SL; Lo LW; Hu YF; Tuan TC; Liao JN; Chung FP; Chen TJ; Chen SA
Int J Cardiol; 2018 Mar; 254():157-161. PubMed ID: 29407081
[TBL] [Abstract][Full Text] [Related]
32. High prevalence of VKORC1*3 (G9041A) genetic polymorphism in north Indians: A study on patients with cardiac disorders on acenocoumarol.
Sehgal T; Hira JK; Ahluwalia J; Das R; Vijayvergiya R; Rana SS; Varma N
Drug Discov Ther; 2015 Dec; 9(6):404-10. PubMed ID: 26781925
[TBL] [Abstract][Full Text] [Related]
33. Genetics and the clinical response to warfarin and edoxaban: findings from the randomised, double-blind ENGAGE AF-TIMI 48 trial.
Mega JL; Walker JR; Ruff CT; Vandell AG; Nordio F; Deenadayalu N; Murphy SA; Lee J; Mercuri MF; Giugliano RP; Antman EM; Braunwald E; Sabatine MS
Lancet; 2015 Jun; 385(9984):2280-7. PubMed ID: 25769357
[TBL] [Abstract][Full Text] [Related]
34. Association of Genetic Polymorphisms of CYP2C9 and VKORC1 with Bleeding Following Warfarin: A Case-Control Study.
Sridharan K; Modi T; Bendkhale S; Kulkarni D; Gogtay NJ; Thatte UM
Curr Clin Pharmacol; 2016; 11(1):62-8. PubMed ID: 26777610
[TBL] [Abstract][Full Text] [Related]
35. Development of a novel composite stroke and bleeding risk score in patients with atrial fibrillation: the AMADEUS Study.
Lip GYH; Lane DA; Buller H; Apostolakis S
Chest; 2013 Dec; 144(6):1839-1847. PubMed ID: 24009027
[TBL] [Abstract][Full Text] [Related]
36. Prediction of stable acenocoumarol dose by a pharmacogenetic algorithm.
Jiménez-Varo E; Cañadas-Garre M; Gutiérrez-Pimentel MJ; Calleja-Hernández MA
Pharmacogenet Genomics; 2014 Oct; 24(10):501-13. PubMed ID: 25089947
[TBL] [Abstract][Full Text] [Related]
37. Major Bleeding in Patients with Non-Valvular Atrial Fibrillation: Impact of Time in Therapeutic Range on Contemporary Bleeding Risk Scores.
Proietti M; Senoo K; Lane DA; Lip GY
Sci Rep; 2016 Apr; 6():24376. PubMed ID: 27067661
[TBL] [Abstract][Full Text] [Related]
38. Prediction of sensitivity to warfarin based on VKORC1 and CYP2C9 polymorphisms in patients from different places in Colombia.
Cifuentes RA; Murillo-Rojas J; Avella-Vargas E
Biomedica; 2016 Mar; 36(1):91-100. PubMed ID: 27622442
[TBL] [Abstract][Full Text] [Related]
39. Genotype-guided therapy improves initial acenocoumarol dosing. Results from a prospective randomised study.
Cerezo-Manchado JJ; Roldán V; Corral J; Rosafalco M; Antón AI; Padilla J; Vicente V; González-Conejero R
Thromb Haemost; 2016 Jan; 115(1):117-25. PubMed ID: 26538428
[TBL] [Abstract][Full Text] [Related]
40. CYP2C9 and VKORC1 gene polymorphism is inessential for bleeding development under conditions of oral application of anticoagulant acenocoumarol in Russian patients at high risk of thromboembolic complications.
Sychev DV; Ignatyev IV; Emelyanov NV; Milovanova VV; Kossovskaya AV; Kukes IV; Tashenova AI; Kukes VG
Bull Exp Biol Med; 2012 Oct; 153(6):886-8. PubMed ID: 23113310
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
